British Journal of Haematology · 2022 · 15 citations · 19 references
Life SciencesHematologyImmunologyAutoimmunityImmunopathologyImmunoregulationCell-mediated ImmunityHelper T Cell SubsetsRegulatory T CellsSpleen PhysiologySplenic PathologyT Cell BiologyImmune-mediated ThrombocytopeniaPeripheral Regulatory T CellsRefractory Immune ThrombocytopeniaSplenic FunctionSurgical Outcome AssessmentSurgical Outcome EvaluationThrombopoietin Receptor AgonistsThrombopoietin Receptor Signaling
Thrombopoietin receptor agonists (TPO-RA) are a valid therapy for immune thrombocytopenia (ITP), due to megakaryocyte stimulation and (poorly characterised) immune-modulatory effects. The spleen is pivotal in the pathogenesis of ITP, yet little is known on its immune microenvironment and on effects of TPO-RA on this organ. To address these topics, we analysed 35 spleens removed for primary refractory ITP. Pre-splenectomy TPO-RA administration correlated with increased splenic regulatory T cells (Tregs), type 2 T-helper cells and histiocyte density and with reduced red pulp sinusoids. Surgical outcome was not associated with TPO-RA administration, other pre-splenectomy therapies and/or Treg density. In conclusion, TPO-RA affect the splenic microenvironment, but this has no impact on splenectomy outcome.
19
Francesco Rodeghiero, Roberto Stasi, Terry Gernsheimer et al. · Blood · 2008 · 2.7K citations · Full text
Medicine, Hematology, Immunology +15
American Society of Hematology 2019 guidelines for immune thrombocytopenia
Cindy Neunert, Deirdra R. Terrell, Donald M. Arnold et al. · Blood Advances · 2019 · 1.3K citations · Full text
T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura
Bob Olsson, Per‐Ola Andersson, Margareta Jernås et al. · Nature Medicine · 2003 · 670 citations
Medicine, Hematology, Immunology +12